BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
31 results:

  • 1. [clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
    Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
    [No Abstract]    [Full Text] [Related]  

  • 2. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/akt pathway attenuation and Myc downregulation.
    Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
    Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The protein landscape of chronic lymphocytic leukemia.
    Meier-Abt F; Lu J; Cannizzaro E; Pohly MF; Kummer S; Pfammatter S; Kunz L; Collins BC; Nadeu F; Lee KS; Xue P; Gwerder M; Roiss M; Hüllein J; Scheinost S; Dietrich S; Campo E; Huber W; Aebersold R; Zenz T
    Blood; 2021 Dec; 138(24):2514-2525. PubMed ID: 34189564
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Targeted inhibition of cooperative mutation- and therapy-induced akt activation in AML effectively enhances response to chemotherapy.
    Estruch M; Reckzeh K; Vittori C; Centio A; Ali M; Engelhard S; Zhao L; Won KJ; Liu P; Porse BT; Theilgaard-Mönch K
    Leukemia; 2021 Jul; 35(7):2030-2042. PubMed ID: 33299144
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia.
    Thomé CH; Ferreira GA; Pereira-Martins DA; Dos Santos GA; Ortiz CA; de Souza LEB; Sobral LM; Silva CLA; Scheucher PS; Gil CD; Leopoldino AM; Silveira DRA; Coelho-Silva JL; Traina F; Koury LC; Melo RAM; Bittencourt R; Pagnano K; Pasquini R; Nunes EC; Fagundes EM; Gloria ABF; Kerbauy FR; Chauffaille ML; Keating A; Tallman MS; Ribeiro RC; Dillon R; Ganser A; Löwenberg B; Valk P; Lo-Coco F; Sanz MA; Berliner N; Faça VM; Rego EM
    Sci Rep; 2020 Jun; 10(1):10315. PubMed ID: 32587277
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Targeting steroid resistance in T-cell acute lymphoblastic leukemia.
    De Smedt R; Morscio J; Goossens S; Van Vlierberghe P
    Blood Rev; 2019 Nov; 38():100591. PubMed ID: 31353059
    [TBL] [Abstract] [Full Text] [Related]  

  • 7.
    Zhou JD; Li XX; Zhang TJ; Xu ZJ; Zhang ZH; Gu Y; Wen XM; Zhang W; Ji RB; Deng ZQ; Lin J; Qian J
    Aging (Albany NY); 2019 May; 11(10):3376-3391. PubMed ID: 31147526
    [No Abstract]    [Full Text] [Related]  

  • 8. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
    Saenz DT; Fiskus W; Manshouri T; Mill CP; Qian Y; Raina K; Rajapakshe K; Coarfa C; Soldi R; Bose P; Borthakur G; Kadia TM; Khoury JD; Masarova L; Nowak AJ; Sun B; Saenz DN; Kornblau SM; Horrigan S; Sharma S; Qiu P; Crews CM; Verstovsek S; Bhalla KN
    Leukemia; 2019 Jun; 33(6):1373-1386. PubMed ID: 30575820
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
    Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
    Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.
    Papaioannou D; Shen C; Nicolet D; McNeil B; Bill M; Karunasiri M; Burke MH; Ozer HG; Yilmaz SA; Zitzer N; Behbehani GK; Oakes CC; Steiner DJ; Marcucci G; Powell BL; Kolitz JE; Carter TH; Wang ES; Mrózek K; Croce CM; Caligiuri MA; Bloomfield CD; Garzon R; Dorrance AM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):E4641-E4647. PubMed ID: 28533390
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic leukemia: A Genome Sequencing Study.
    Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
    PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and clinical outcome in Acute Lymphoblastic leukemia.
    Chen D; Zheng J; Gerasimcik N; Lagerstedt K; Sjögren H; Abrahamsson J; Fogelstrand L; Mårtensson IL
    PLoS One; 2016; 11(9):e0162638. PubMed ID: 27611867
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
    D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
    J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
    Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
    Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation, apoptosis and invasion.
    Feng Y; Xu X; Zhang Y; Ding J; Wang Y; Zhang X; Wu Z; Kang L; Liang Y; Zhou L; Song S; Zhao K; Ye Q
    Sci Rep; 2015 Mar; 5():9429. PubMed ID: 25800793
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
    Dzneladze I; He R; Woolley JF; Son MH; Sharobim MH; Greenberg SA; Gabra M; Langlois C; Rashid A; Hakem A; Ibrahimova N; Arruda A; Löwenberg B; Valk PJ; Minden MD; Salmena L
    Leukemia; 2015 Jul; 29(7):1485-95. PubMed ID: 25736236
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways.
    Li J; Chen Y; Chen B; Chen C; Qiu B; Zheng Z; Zheng J; Liu T; Wang W; Hu J
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):283-93. PubMed ID: 25217883
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts.
    Zabkiewicz J; Pearn L; Hills RK; Morgan RG; Tonks A; Burnett AK; Darley RL
    Haematologica; 2014 May; 99(5):858-64. PubMed ID: 24334295
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.
    Keune WJ; Sims AH; Jones DR; Bultsma Y; Lynch JT; Jirström K; Landberg G; Divecha N
    Cancer Res; 2013 Dec; 73(23):6913-25. PubMed ID: 24127122
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.